Clinical trial NCT02292771: A Randomized Study Comparing the Efficacy and Safety of Retosiban Versus Atosiban for Women in Spontaneous Preterm Labour
Official title: Randomized, Double-blind, Multicenter, Phase III Study Comparing the Efficacy and Safety of Retosiban Versus Atosiban Therapy for Women in Spontaneous Preterm Labor
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Obstetric Labour, Premature
Keywords: Spontaneous Preterm Labor
retosiban
GSK221149
atosiban
Lead sponsor: GlaxoSmithKline
Sponsor class: INDUSTRY
Collaborators: name: PPD Development, LP
First posted: 2014-11-17
Enrollment: 97
Sex: FEMALE
Minimum age (years): 12
Maximum age (years): 45
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary objective of this study is to demonstrate the superiority of retosiban to prolong pregnancy in females with spontaneous preterm labor compared with atosiban. This objective is based on the hypothesis that prolonging the time to delivery in the absence of harm may benefit the newborn, particularly in women who experience spontaneous preterm labor at early gestational ages (GA). This study is designed to test this hypothesis through a direct comparison with atosiban, a mixed oxytocin vasopressin antagonist indicated for short-term use to delay imminent preterm birth in women between 24\^0/7 and 33\^6/7 weeks' gestation in preterm labor. This is a randomized, double-blind, double-dummy study, which consists of 6 phases: Screening, Inpatient Randomized Treatment, Post Infusion Assessment, Delivery, Maternal Post Delivery Assessment, and Neonatal Medical Review. Approximately 330 females will be randomly assigned to retosiban or atosiban treatment in a 1:1 ratio. The duration of any one subject's (maternal or neonatal) participation in the study will be variable and dependent on GA at study entry and the date of delivery.


Eligibility criteria: Inclusion Criteria:

* Signed and dated written informed consent is required prior to a subject's participation in the study and the performance of any protocol specific procedures. Adolescents aged 12 to 17 years must provide written agreement to participate in the study in accordance with applicable regulatory and country or state requirements. Subjects will also be asked to sign a release for medical records at the time of consenting to allow access to both the maternal and neonatal records including information about delivery and infant care as well as information collected prior to the consent having been signed.
* Females aged 12 to 45 years, with an uncomplicated, singleton pregnancy and intact membranes in preterm labor (Note: This protocol includes pregnant adolescents, aged 12 to 17 years, as appropriate, based on national or local regulations.).
* Gestational age between 24\^0/7 and 33\^6/7 weeks as determined by known fertilization date, either in vitro fertilization or intrauterine insemination, last menstrual period confirmed by the earliest ultrasound prior to 24\^0/7 weeks' gestation, or the earliest ultrasound alone prior to 24\^0/7 weeks' gestation, whichever is the most accurate method available for each subject. In situations where prenatal ultrasound records are not available at the time the subject presents, the investigator will make every effort to obtain these records (either via computer records, directly from the subject's primary care obstetrician, or via telephone). However, in cases in which these records are not readily available (e.g., off hours, holiday), it is within the investigator's discretion to use GA based on a verbal history from the subject with the intent of getting confirmation from the medical records as soon as possible.
* Subjects must be diagnosed with preterm labor according to both of the following criteria:

Regular uterine contractions at a rate of \>=4 contractions of at least 30 seconds duration during a 30-minute interval confirmed by tocodynamometry

AND at least 1 of the following:

Cervical dilation \>=2 centimeter (cm) and \<=4 cm by digital cervical examination or If \<2 cm dilation by digital cervical examination, a cervical change consisting of an increase of at least 25% effacement or 1 cm dilation

* Treatment naïve subjects and subjects not adequately responding to tocolytics other than atosiban (e.g., transfers from other care units) during their current episode of preterm labor may be eligible for the study. Historical failure of a tocolytic treatment in a previous episode of preterm labor is not a required inclusion criterion. Tocolytic failure is defined by progressive cervical changes or continuing uterine contractions.

Exclusion Criteria:

* Fever with a temperature greater than 100.4°fahrenheit (F) (38°Celcius \[C\]) for more than 1 hour or \>=101°F (38.3°C) in the 24 hours prior to the start of study treatment.
* Women with maternal-fetal conditions that potentially necessitate the need for delivery, such as pre-eclampsia or fetal compromise
* A fetus with any diagnosis, condition, treatment, or other factor that in the opinion of the investigator has the potential to affect or confound assessments of efficacy or safety (e.g., nonreassuring fetal status, intrauterine growth restriction, major congenital anomaly).
* Preterm premature rupture of membranes
* Women with any confirmed or suspected contraindication to prolongation of pregnancy, such as placental abruption, chorioamnionitis, or placenta previa
* Evidence of polyhydramnios (amniotic fluid index \[AFI\] \>25 cm) or oligohydramnios (AFI \<5 cm).
* Women with co-morbid medical or obstetric conditions that in the opinion of the investigator have the potential to complicate the pregnancy course and outcomes, such as uncontrolled hypertension, uncontrolled diabetes (if known, history of glycosylated hemoglobin \>8% at any time during pregnancy), or compromise the safety of the subject, such as underlying cardiovascular disorder (specifically ischemic cardiac disease, congenital heart disease, pulmonary hypertension, valvular heart disease, arrhythmias, and cardiomyopathy).
* Women with a history of substance abuse or urine drug screen findings suggestive of substance abuse that may either be implicated as the cause of preterm labor (e.g., abuse of cocaine or methamphetamines) or have the potential to complicate the pregnancy outcome (e.g., alcohol abuse or opioid addiction).
* Women with any diagnosis, condition, treatment, or other factor that in the opinion of the investigator has the potential to affect or confound assessments of efficacy or safety.
* Women with documented active hepatitis B or hepatitis C viral infection, unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice), cirrhosis, known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
* History of sensitivity to the IPs or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GlaxoSmithKline (GSK)/PPD medical monitor, contraindicates their participation.

Primary outcomes:
measure: Time to Delivery From the Start of Investigational Product (IP) Administration
timeFrame: Up to 17 weeks
Secondary outcomes:
measure: Number of Participants With Births Prior to 37 0/7 Weeks Gestation
timeFrame: Up to 13 weeks
measure: Number of Participants With Births at Term
timeFrame: Up to 17 weeks
measure: Length of Neonatal Hospital Stay
timeFrame: Up to 28 days post estimated date of delivery (EDD) of 40 0/7 weeks gestation
measure: Number of Neonates With Composite Neonatal Morbidity and Mortality
timeFrame: Up to 28 weeks after EDD (40 weeks gestation)
measure: Number of Neonates With Any Composite Neonatal Morbidity and Mortality, Excluding RDS
timeFrame: Up to 28 weeks after EDD (40 weeks gestation)
measure: Number of Neonates With Each Individual Component of Composite Neonatal Morbidity and Mortality
timeFrame: Up to 28 weeks after EDD (40 weeks gestation)
measure: Length of Stay in Specialized Care Unit
timeFrame: Up to 28 days post EDD (40 0/7 weeks gestation)
measure: Number of Newborn Participants With Hospital Readmission
timeFrame: Up to 28 days of EDD (40 0/7 weeks gestation)
measure: Number of Participants With Births Prior to 28 0/7 Weeks Gestation
timeFrame: Up to 4 weeks
measure: Number of Participants With Births Prior to 32 0/7 Weeks Gestation
timeFrame: Up to 8 weeks
measure: Number of Participants With Births Prior to 35 0/7 Weeks Gestation
timeFrame: Up to 11 weeks
measure: Number of Participants With Births <=7 Days From the First Study Treatment
timeFrame: Up to 7 days
measure: Number of Participants With Births <=48 Hours From the First Study Treatment
timeFrame: Up to 48 hours
measure: Number of Participants With Births <=24 Hours From the First Study Treatment
timeFrame: Up to 24 hours
measure: Number of Maternal Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs)
timeFrame: Up to 6 weeks after delivery
measure: Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) in Maternal Participants
timeFrame: Baseline and up to 1 week
measure: Change From Baseline in Heart Rate in Maternal Participants
timeFrame: Baseline and up to 1 week
measure: Change From Baseline in Respiratory Rate in Maternal Participants
timeFrame: Baseline and up to 1 week
measure: Change From Baseline in Temperature in Maternal Participants
timeFrame: Baseline and up to 1 week
measure: Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Count in Maternal Participants
timeFrame: Baseline and up to 1 week
measure: Change From Baseline in Erythrocytes in Maternal Participants
timeFrame: Baseline and up to 1 week
measure: Change From Baseline in Hemoglobin and Erythrocyte Mean Corpuscular Hemoglobin Concentration (MCHC) in Maternal Participants
timeFrame: Baseline and up to 1 week
measure: Change From Baseline in Erythrocyte Mean Corpuscular Volume (MCV) and Mean Platelet Volume (MPV) in Maternal Participants
timeFrame: Baseline and up to 1 week
measure: Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LDH) Levels in Maternal Participants
timeFrame: Baseline and up to 1 week
measure: Change From Baseline in Albumin and Protein Levels in Maternal Participants
timeFrame: Baseline and up to 1 week
measure: Change From Baseline in Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Magnesium, Phosphate and Sodium Level in Maternal Participants
timeFrame: Baseline and up to 1 week
measure: Change From Baseline in Direct Bilirubin, Bilirubin, Indirect Bilirubin, Creatinine and Urate Levels in Maternal Participants
timeFrame: Baseline and up to 1 week
measure: Number of Maternal Participants With AEs of Special Interest (AESI)
timeFrame: Up to 6 weeks post-delivery
measure: Number of Maternal Participants With Disease Related AEs (DRE)
timeFrame: Up to 6 weeks post-delivery
measure: Number of Participants With Fetal Non-serious AEs and SAEs
timeFrame: Up to 17 weeks
measure: Number of Participants With Fetal AESI
timeFrame: Up to 17 weeks
measure: Neonatal APGAR Scores
timeFrame: Up to 5 minutes after birth
measure: Weight of Neonates
timeFrame: Up to 17 weeks
measure: Head Circumference of Neonates
timeFrame: Up to 17 weeks
measure: Number of Neonatal Participants With Non-serious AEs and SAEs
timeFrame: Up to 28 days after the EDD of 40 weeks gestation
measure: Number of Neonatal Participants With AESI
timeFrame: Up to 28 days after EDD of 40 weeks gestation
measure: Number of Neonatal Participants With DRE
timeFrame: Up to 28 days after EDD of 40 weeks gestation
measure: Maternal Length of Stay in Hospital
timeFrame: Up to 28 days post EDD (40 0/7 weeks gestation)
measure: Number of Participants Admitted to Particular Hospital Unit
timeFrame: Up to 28 days post EDD (40 0/7 weeks gestation)
measure: Retosiban Clearance
timeFrame: Day 1 (2 to 4 hours, 10 to 14 hours) and Day 2 (22 to 26 hours, and 48 to 54 hours) post-infusion
measure: Volume of Distribution of Retosiban
timeFrame: Day 1 (2 to 4 hours, 10 to 14 hours) and Day 2 (22 to 26 hours, and 48 to 54 hours) post-infusion
Other outcomes:
Locations:
city: Brugge
country: Belgium
facility: GSK Investigational Site
city: Bruxelles
country: Belgium
facility: GSK Investigational Site
city: Freiburg
country: Germany
facility: GSK Investigational Site
state: Baden-Wuerttemberg
city: Jena
country: Germany
facility: GSK Investigational Site
state: Thueringen
city: Hamburg
country: Germany
facility: GSK Investigational Site
city: Haifa
country: Israel
facility: GSK Investigational Site
city: Holon
country: Israel
facility: GSK Investigational Site
city: Kfar Saba
country: Israel
facility: GSK Investigational Site
city: Petach Tikva
country: Israel
facility: GSK Investigational Site
city: Safed
country: Israel
facility: GSK Investigational Site
city: Tel Aviv
country: Israel
facility: GSK Investigational Site
city: Siena
country: Italy
facility: GSK Investigational Site
state: Toscana
city: Monza
country: Italy
facility: GSK Investigational Site
city: Seoul
country: Korea, Republic of
facility: GSK Investigational Site
city: Seoul
country: Korea, Republic of
facility: GSK Investigational Site
city: Sungnam
country: Korea, Republic of
facility: GSK Investigational Site
city: Monterrey
country: Mexico
facility: GSK Investigational Site
state: Nuevo León
city: Ciudad Obregon
country: Mexico
facility: GSK Investigational Site
state: Sonora
city: Zaragoza
country: Spain
facility: GSK Investigational Site
city: Uppsala
country: Sweden
facility: GSK Investigational Site
city: Sheffield
country: United Kingdom
facility: GSK Investigational Site
Study officials:
affiliation: GlaxoSmithKline
name: GSK Clinical Trials
role: STUDY_DIRECTOR
References: